Navigation Links
ThromboGenics Announces Business Update and 2008 Full Year Results
Date:3/12/2009

LEUVEN, Belgium, March 12 /PRNewswire-FirstCall/ --

- ThromboGenics Reports Pre-Tax Profit of EUR12.2 Million For 2008

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments that will make a real difference to patient care in a number of important therapeutic areas, is today issuing a business update and its financial results for the full year ending December 31, 2008.

During the last twelve months, ThromboGenics has made considerable progress across all aspects of its business culminating in the recent start of the Phase III clinical development program for its lead product microplasmin in back of the eye disease. The decision to start the Phase III program was based on the positive Phase II clinical results which were announced over the course of 2008.

In June 2008, ThromboGenics announced a further important corporate milestone, the signing of a high value strategic alliance with Roche for its novel anti-cancer antibody TB-403 (anti-PIGF). This deal, which generated an upfront payment of EUR30 million, has provided significant funding to allow ThromboGenics to invest in its other development programs.

The upfront payment from the Roche deal has enabled ThromboGenics to report a pre-tax profit of EUR 12.2 million in 2008.

Given its recent progress, ThromboGenics is confident that over the next eighteen months it will be able to generate significant shareholder value as it continues to maximize the value of its exciting product pipeline.

Business Highlights

Clinical Highlights

Microplasmin - Eye Disease: Positive results announced in Phase II clinical trials for back of the eye indications. Positive results were reported in ThromboGenics' Phase IIb (MIVI III) trial in patients with a number of back of the eye conditions. The trial show
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
2. ThromboGenics N.V.: Business Update
3. ThromboGenics Announces Half Year Results 2008
4. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
5. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
6. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
7. ThromboGenics N.V. - Business Update
8. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
9. ThromboGenics Announces 2007 Full Year Results
10. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
11. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... California , January 15, 2014 Oxford ... today announced the appointment of Thomas C Reynolds MD, PhD ... years, development experience gained in the biotechnology industry, most recently ... am delighted to welcome Tom at this transformative time for ...
(Date:1/15/2014)... England , January 15, 2014 A ... win races on the Formula 1 track could help to ... McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based in ... by healthcare provider Simplyhealth. Telemetry technology, which is ...
(Date:1/15/2014)... Rochester, NY (PRWEB) January 15, 2014 The ... cause a major disease. One of these latent viruses is ... is rheumatoid arthritis (RA). Rheumatoid arthritis (RA) is a chronic ... the theory, a study found that RA patients have high ...
(Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... -- (May 30, 2010) -- In a development that ... researchers from Rice University and the Technion-Israel Institute of ... quantities of one-atom-thick sheets of carbon called graphene. ... Nature Nanotechnology . When stacked together, graphene sheets ...
... ... a detailed “road map” defining all aspects of the future 110-acre Livermore Valley Open ... site planning, and real estate development planning, as well as maintenance and operations planning. ... San Francisco, ...
... May 28 BioSpace.com is putting the nation,s Middle-Atlantic region on ... (Logo:   http://www.newscom.com/cgi-bin/prnh/20040907/CLTU006LOGO ) , ... The leading career Web site for the life sciences ... edition and highlighting multiple companies within Washington D.C. , Delaware , ...
Cached Biology Technology:Liquid method: pure graphene production 2Flad Architects Awarded Livermore Valley Open Campus Master Plan 2BioSpace Launches 10th Campaign Map for the Mid-Atlantic 2BioSpace Launches 10th Campaign Map for the Mid-Atlantic 3
(Date:4/22/2014)... The Federation of American Societies for Experimental Biology (FASEB) ... (FY) 2013 highlighting how funding from the National Institutes ... DC, and Puerto Rico. "FASEB is pleased to make ... the significance of NIH to their state," said FASEB ... nation,s leading source for biomedical research funding, investing ...
(Date:4/22/2014)... As President Barack Obama begins a trip to ... strategic pivot to the Pacific, officials at the ... Asia-Pacific Technology and Education Partnership (APTEP) as an ... United States and its allies in the region. ... partnerships across the Asia-Pacific region, supports the development ...
(Date:4/22/2014)... shown that exposure to environmental enrichment can ... improving learning and memory. Previous studies have ... in the superficial layer of the cerebral ... pigs, and these neurons exhibit very weak ... conditions. Whether environmental enrichment has an impact ...
Breaking Biology News(10 mins):Full power: Alternative energy partnerships flourish in Asia 2Full power: Alternative energy partnerships flourish in Asia 3
... to have a warning sign before a structural system fails, ... having a sign that,s easy to read is a challenge. ... of Pennsylvania and Duke University bioengineers and chemists, such warning can ... The study was conducted by professor Daniel Hammer and ...
... particularly chronic pain, very differently. The ability of some ... men. While it has been recognized since the mid-nineties ... than men, the reason for this difference was largely ... opioid receptors, which are located on nerves that transmit ...
... NYU School of Medicine have discovered the cellular mechanisms that ... The study,s findings are published in the August 18 issue ... a new explanation on how bacteria generate mutations and adapt ... it touches on several different fields of molecular biology at ...
Cached Biology News:Penn molecular scientists develop color-changing stress sensor 2Penn molecular scientists develop color-changing stress sensor 3SUNY Downstate researchers identify possible new targets for treating pain in women 2NYU Langone researchers reveal a new mechanism of genomic instability 2
... PCR carry-over contamination, which prevents false ... products from previous PCR amplifications without ... improves amplification ,Optimized for use with ... instrument systems , The GeneAmp PCR ...
... that catalyzes the hydrolysis of,starch to ... dextrins. The,level of a-amylase in various ... of,clinical significance in the diagnosis of ... and microbial a-amylases are,important enzymes for ...
... The Thermo Labsystems Wellmix is a ... and time settings. The shaking speed is ... shaking frequency, high speed and a small ... assays. The shaking time is quick and ...
Rabbit polyclonal to STUB1 ( Abpromise for all tested applications). entrezGeneID: 10273 SwissProtID: Q9UNE7...
Biology Products: